Alumis (ALMS) Consolidated Net Income (2023 - 2025)
Alumis (ALMS) reported Consolidated Net Income of -$93.0 million for Q4 2025, up 1.89% year-over-year from -$91.2 million in Q4 2024, and up 16.06% on a QoQ basis from -$110.8 million in Q3 2025.
Alumis (ALMS) has 3 years of Consolidated Net Income data on file, last reported at -$93.0 million in Q4 2025.
- Quarterly Consolidated Net Income rose 1.89% year-over-year to -$93.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$245.9 million (up 15.77% YoY) and the FY2025 annual result came in at -$243.3 million, up 17.3% from the prior year.
- Consolidated Net Income advanced to -$93.0 million in Q4 2025 per ALMS's latest filing, from -$110.8 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $59.3 million in Q2 2025 and bottomed at -$110.8 million in Q3 2025.
- The 3-year median for Consolidated Net Income is -$56.5 million (2024), against an average of -$59.9 million.
- The widest annual swing landed in 2024, when Consolidated Net Income plunged 136.12%; it then surged 204.98% in 2025.
- Tracing ALMS's Consolidated Net Income over 3 years: stood at -$40.1 million in 2023, then sank by 136.12% to -$94.8 million in 2024, then increased by 1.89% to -$93.0 million in 2025.
- Per Business Quant, the three latest ALMS Consolidated Net Income figures stand at -$93.0 million (Q4 2025), -$110.8 million (Q3 2025), and $59.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Alumis | 1.84 Bn | 1.75 Bn | - | -92.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -92.97 Mn |
| Sep 30, 2025 | -110.75 Mn |
| Jun 30, 2025 | 59.32 Mn |
| Mar 31, 2025 | -101.53 Mn |
| Dec 31, 2024 | -94.76 Mn |
| Sep 30, 2024 | -93.12 Mn |
| Jun 30, 2024 | -56.51 Mn |
| Mar 31, 2024 | -47.59 Mn |
| Dec 31, 2023 | -40.13 Mn |
| Sep 30, 2023 | -43.76 Mn |
| Jun 30, 2023 | -36.71 Mn |